Your Source for Venture Capital and Private Equity Financings

Venture Capital News: Vera Therapeutics Launches with $80M in Series C

2021-01-22
SOUTH SAN FRANCISCO, CA, Vera Therapeutics announced its launch backed by $80 million Series C financing led by Abingworth.
Vera Therapeutics, a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP.

Other investors included Sofinnova Investments, Longitude Capital, Fidelity Management & Research Company LLC, Surveyor Capital (a Citadel company), Octagon Capital, Kleiner Perkins, GV (formerly Google Ventures), and Alexandria Venture Investments.

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases. Vera's mission is to develop and commercialize transformative new therapies that improve patients' lives. Vera's lead program is atacicept, a fusion protein that is a dual inhibitor of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which is in development for IgA nephropathy (IgAN), also known as Berger's disease.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors